Raymond James downgraded Korro Bio (KRRO) to Market Perform from Strong Buy without a price target after the Phase 1/2a REWRITE study showed KRRO-110 did not increase total alpha-1 antitrypsin above the protective threshold. The firm now sees a level of uncertainty associated with Korro’s overall platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: